Compounds

A compound of the formula:

• wherein
• one of R1 and R2 is a 4-pyridyl ring, which ring is optionally substituted with one or two substituents each of which is independently selected from C1-4 alykl, halo, C1-4 alkoxy, C1-4 alkylthio, CH2OR8, NH2, mono- or di-C1-6-alkylamino or N-heterocyclyl ring selected from pyrrolidine, piperidine, piperazine, morpholine, imidazolidine, and pyrazolidine;
• the other of R1 and R2 is selected from an optionally substituted phenyl ring, or naphthyl ring, which ring is substituted by one or two substituents, each of which is independently selected, and which, for a 4-phenyl, 4-naphth-1-yl or 5-naphth-2-yl substituent, is halo, nitro, cyano, C(Z)NR7R17, C(Z)OR23, (CR10R20)nCOR36, SR5, S(O)R5, OR36, halo-substituted C1-4 alkyl, C1-4 alkyl, ZC(Z)R36, NR10C(Z)R23, or (CR10R20)nNR10R20 and which, for other positions of substitution, is halo, (CR10R20)nnitro, (CR10R20)ncyano, (CR10R20)nC(Z)NR16R26, (CR10R20)nC(Z)OR18, (CR10R20)nCOR25, (CR10R20)n—S(O)mR8, (CR10R20)nOH, (CR10R20)nOR25, halo-substituted-C1-4 alkyl, C1-4 alkyl, (CR10R20)nNR10C(Z)R25, (CR10R20)nNHS(O)mR6, (CR10R20)nNHS(O)mNR7R17, (CR10R20)nNR6S(O)mR6, (CR10R20)nNR6S(O)m′NR7R17;
• (CR10R20)nZC(Z)R18 or (CR10R20)nNR7R17;
• n is 0 or an integer of 1 or 2;
• m is 0 or an integer of 1 or 2;
• m′ is an integer of 1 or 2;
• R3 is Q-(Y1)t;
• Q is a pyridyl group;
• t is an integer having a value of 1 to 3;
• R4 is hydrogen, C1-10alkyl, halo-substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C3-7cycloalkylC1-10 alkyl, C5-7 cycloalkenyl, C5-7cycloalkenyl-C1-10 alykl, aryl, arylC1-10 alkyl, (CR10R20)n′OR12, (CR10R20)nOR13, (CR10R20)nS(O)mR18, (CR10R20)nNHS(O)2R18, (CR10R20)nNR16R26, (CR10R20)nNO2, (CR10R20)nCN, (CR10R20)n′SO2R18, (CR10R20)nS(O)m′NR16R26, (CR10R20)nC(Z)R13, (CR10R20)nOC(Z)R13, (CR10R20)nC(Z)OR13, (CR10R20)nC(Z)NR16R26, (CR10R20)nC(Z)NR13OR9, (CR10R20)nNR10C(Z)R11, (CR10R20)nNR10C(Z)NR16R26, (CR10R20)nN(OR6)C(Z)NR16R26, (CR10R20)nN(OR6)C(Z)R13, (CR10R20)nC(═NOR6)R13, (CR10R20)nNR10C(═NR19)NR16R26, (CR10R20)nOC(Z)NR16R26, (CR10R20)nNR10C(Z)NR16R26, (CR10R20)nNR10C(Z)OR10, wherein the aryl, arylalkyl, cyclcoalkyl, cycloalkyl alkyl groups may be optionally substituted;
• R6 is C1-10 alkyl, C3-7 cycloalkyl, aryl, arylC1-10alkyl;
• R5 is hydrogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl or NR7R17, excluding the moieties—SR5 being —SNR7R17 and —SOR5 being —SOH;
• R16 and R26 are independently hydrogen, or C1-4alkyl or R16 and R26 together with the nitrogen to which they are attached form a heterocyclic selected from pyrrolidine, piperidine, piperazine, morpholine, imidazolidine, and pyrazolidine;
• Y1 is independently selected from hydrogen, C1-5 alkyl, halo-substituted C1-5 alkyl, halogen, or —(CR10R20)nY2;
• Y2 is hydrogen, halogen, OR8, NO2, S(O)m′R11, SR8, S(O)m′OR8, S(O)mNR8R9, NR8R9, O(CR10R20)n′NR8R9, C(O)R8, CO2R8, CO2(CR10R20)m″CONR8R9, ZC(O)R8, CN, C(Z)NR8R9, NR10C(Z)R8, C(Z)NR8OR9, NR10C(Z)NR8R9, NR10S(O)m′R11, N(OR21)C(Z)NR8R9, N(OR21)C(Z)R8, C(═NOR21)R8, NR10C(═NR15)SR11, NR10C(═NR15)NR8R9, NR10C(═CR14R24)SR11, NR10C(═CR14R24)NR8R9, NR10C(O)C(O)NR8R9, NR10C(O)C(O)OR10, C(═NR13)NR8R9, C(═NOR13)NR8R9, C(═NR13)ZR11, OC(Z)NR8R9, NR10S(O)mCF3, NR10C(Z)OR10, 5-(R18)-1,2,4-oxadizaol-3-yl or 4-(R12)-5-(R18R19)-4,5-dihydro-1,2,4-oxadiazol-3-yl;
• n′ is 0 or an integer having a value of 1 to 10;
• m″ is an integer having a value of 1 to 10;
• R7 and R17 is each independently selected from hydrogen or C1-4 alkyl or R7 and R17 together with the nitrogen to which they are attached form a heterocyclic ring selected from pyrrolidine, piperidine, piperazine, morpholine, imidazolidine, and pyrazolidine;
• R8 is hydrogen, C1-10 alkyl, C3-7 cycloalkyl, aryl, arylC1-10alkyl;
• R9 is hydrogen, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylalkyl, or R8 and R9 may together with the nitrogen to which they are attached form a heterocyclic selected from pyrrolidine, piperidine, piperazine, morpholine, imidazolidine, and pyrazolidine;
• R10 and R20 is each independently selected from hydrogen or C1-4 alkyl;
• R11 is C1-10 alkyl, halo-substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C5-7, aryl, aryl C1-10alkyl;
• R12 is hydrogen, —C(Z)R13, optionally substituted C1-4 alkyl, optionally substituted aryl, optionally substituted aryl-C1-4 alkyl, or S(O)2R18;
• R13 is hydrogen, C1-10alkyl, C3-7 cycloalkyl, aryl, arylC1-10alkyl;
• R14 and R24 is each independently selected from hydrogen, alkyl, nitro or cyano;
• R15 is hydrogen, cyano, C1-4 alkyl, C3-7 cycloalkyl or aryl;
• R18 is C1-10 alkyl, C3-7 cycloalkyl, aryl, arylC1-10alkyl;
• R19 is hydrogen, cyano, C1-4 alkyl, C3-7 cycloalkyl or aryl;
• R21 is hydrogen, a pharmaceutically acceptable cation, C1-10 alkyl, C3-7 cycloalkyl, aryl, aryl C1-4 alkyl, aroyl, or C1-10 alkanoyl;
• R22 is R10 or C(Z)-C1-4 alkyl;
• R23 is C1-4 alkyl, halo-substituted-C1-4 alkyl, or C3-7 cycloalkyl;
• R25 is C1-10 alkyl, halo-substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylC1-10alkyl, (CR10R20)nOR8, (CR10R20)nS(O)mR18, (CR10R20)nNHS(O)2R18, (CR10R20)nNR7R17;
• wherein the aryl, or arylalkyl may be optionally substituted;
• R36 is hydrogen or R23;
• Z is oxygen;
• Aryl is phenyl or naphthyl;
• or a pharmaceutically acceptable salt thereof.